PASSAGE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.2 USD | -5.51% |
|
-11.76% | +18.81% |
| Mar. 04 | Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 04 | Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 73.93M |
|---|---|---|---|---|---|
| Net income 2024 * | -76M | Net income 2025 * | -89M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 51.6M | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.98
x | P/E ratio 2025 * |
-1.23
x | Employees | 58 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.68% |
More Fundamentals
* Assessed data
More news
Latest transcript on Passage Bio, Inc.
More recommendations
More press releases
| 1 day | -5.51% | ||
| 1 week | -11.76% | ||
| Current month | -11.11% | ||
| 1 month | -17.81% | ||
| 3 months | +28.37% | ||
| 6 months | +82.09% | ||
| Current year | +18.81% |
1 week
1.14
1.37
1 month
1.141.61
Current year
0.841.79
1 year
0.581.79
3 years
0.5819.84
5 years
0.5838.23
10 years
0.5838.23
| Managers | Title | Age | Since |
|---|---|---|---|
William Chou
CEO | Chief Executive Officer | 51 | 22-10-09 |
James M. Wilson
FOU | Founder | - | 17-06-30 |
| Director of Finance/CFO | 48 | 21-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Maxine Gowen
CHM | Chairman | 66 | 21-02-17 |
Michael Kamarck
BRD | Director/Board Member | 73 | 22-07-01 |
Saqib Islam
BRD | Director/Board Member | 54 | 19-03-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 1.2 | -5.51% | 122,534 |
| 24-04-17 | 1.27 | +2.42% | 59,174 |
| 24-04-16 | 1.24 | +0.81% | 66,554 |
| 24-04-15 | 1.23 | -8.21% | 97,728 |
| 24-04-12 | 1.34 | -1.47% | 51,784 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimerâs disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.2
USD
Average target price
7
USD
Spread / Average Target
+483.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.81% | 73.93M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -2.04% | 21.66B | |
| -18.35% | 20.77B | |
| -8.72% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- PASG Stock
